Press Release
Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
December 2, 2009
Abbott Park, Illinois (NYSE: ABT)
— Abbott's Ibis technology for detecting and characterizing a vast array of
microorganisms has been named one of the top innovations in 2009 by The
Scientist magazine. A panel of expert judges evaluated a broad range of
life science technologies to determine the year's top innovations, with the
winners unveiled in the publication's December issue and online at www.the
scientist.com/top10innovations.
"The Scientist is really happy to present our innovation awards
for the second time," said Alison McCook, deputy editor. "This year's
list captures a wide range of products, from imaging and genomics to other
tools that stunningly capture both intracellular and extracellular processes.
We look forward to seeing how these products will impact the life
sciences."
Abbott's Ibis system (now marketed under the PLEX ID trade name) was
recognized for the honor, in part, because it is designed to detect and
characterize a broad range of microorganisms in a given sample, including
viruses, bacteria and fungi.
"Science is the foundation for everything we do at Abbott, and we're
proud to be honored for the distinguished work that our scientists and
engineers do to provide important advances across the spectrum of care,"
said Edward Michael, executive vice president, Diagnostics, Abbott.
Earlier this year, the Ibis technology was named overall Gold winner of the
2009 Wall Street Journal Technology Innovation Awards.
The PLEX ID is a high-throughput system based on a combination of
technologies including polymerase chain reaction (PCR) and mass spectrometry
analysis.
The system is designed to address a significant unmet need by providing
test results in six to seven hours instead of three or more days as often
required with current culturing methods.
PLEX ID is currently not intended for use in diagnostic procedures.
Commercial applications for the system include tests developed for use in
unregulated areas such as epidemiologic surveillance, biological research,
environmental testing, and forensic research.
About Abbott
Abbott (NYSE: ABT)
is a global, broad-based health care company devoted to the discovery,
development, manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company employs more than
72,000 people and markets its products in more than 130 countries.
Media:
Don Braakman |
(847) 937-0080 |
